Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus VESICARE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus VESICARE.
ANTRENYL vs VESICARE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
Competitive antagonist at muscarinic acetylcholine receptors (M1-M5), with selectivity for M3 receptors over M2. Inhibits bladder detrusor muscle contraction, increasing bladder capacity and reducing urinary urgency.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
5 mg orally once daily; may increase to 10 mg once daily if needed.
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
Terminal elimination half-life is approximately 45 hours (range 33–57 hours), supporting once-daily dosing.
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Approximately 70% of an oral dose is excreted in urine (mainly as metabolites, <15% unchanged) and 25% in feces.
Category C
Category C
Anticholinergic
Anticholinergic